Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Personalis, Inc. PSNL

Healthcare — Diagnostics & Research
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
2.74
Total sells
8.51
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — — — — — —
Sell — 2 — 1 — — — 2 4 2 — —
Insider Ownership
31.76%

Capital & Financial Ratios

Market Cap
1,760.00
Revenue
69.67
Net Income
(107.18)
Free Cash Flow
(100.85)
Net Debt
(212.66)
Current Ratio
5.28
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
24.82
P/B ratio
7.35
Past 5Y EPS Growth
(11.31%)
This Y EPS Growth
(18.57%)
Next Y EPS Growth
12.98%
Next 5Y EPS Growth
10.38%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 114.18 185.01 239.95 212.66
Receivables 17.73 8.14 16.20 15.10
Inventory 10.47 5.94 6.14 9.64
Other — — — —
146.74 203.02 267.95 245.05
2023 2024 2025 Q'26
Payables 14.92 6.40 12.99 16.01
ST’ Debt — — — —
Other 8.37 3.10 1.56 3.40
47.23 31.13 39.63 46.39
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 15.47 22.36 — —
—
’25 20.61 17.20 14.50 17.35
69.65
’24 19.53 22.58 25.71 16.80
84.61
’23 18.86 16.70 18.25 19.68
73.48
’22 15.23 18.24 14.86 16.72
65.05
’21 20.88 21.67 22.26 20.68
85.49
’20 19.16 19.50 19.82 20.18
78.65
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (22.48) (25.77) — —
—
’25 (17.96) (12.93) (21.80) (22.25)
(74.95)
’24 (20.41) (10.74) (6.20) (7.80)
(45.15)
’23 (15.74) (10.41) (16.68) (13.42)
(56.26)
’22 (11.36) (27.35) (14.76) (16.76)
(70.23)
’21 (11.74) (25.93) (17.88) (15.27)
(70.83)
’20 (8.64) (15.35) (16.12) (2.53)
(42.65)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (25.55) (29.55) — —
—
’25 (20.47) (13.22) (23.43) (22.32)
(79.45)
’24 (20.52) (10.51) (6.44) (9.04)
(46.51)
’23 (19.52) (13.15) (17.55) (16.94)
(67.17)
’22 (19.99) (37.66) (36.18) (26.30)
(120.13)
’21 (12.18) (30.04) (20.84) (18.85)
(81.91)
’20 (8.72) (16.13) (17.68) (3.37)
(45.90)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.29) (0.30) — —
—
’25 (0.18) (0.23) (0.24) (0.26)
(0.91)
’24 (0.26) (0.24) (0.64) (0.23)
(1.37)
’23 (0.61) (0.50) (0.60) (0.54)
(2.25)
’22 (0.63) (0.60) (0.58) (0.67)
(2.48)
’21 (0.29) (0.34) (0.40) (0.45)
(1.49)
’20 (0.29) (0.29) (0.27) (0.34)
(1.20)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 1.73 0.89 1.12 2.83 — — —
Low Price
— — — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 14.57 4.31 7.20 11.40 — — —
High Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 399 225 229 260 — — —
Employees
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.16 0.33 0.37 0.27 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.05 73.48 84.61 69.65 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.52% 24.78% 31.70% 22.65% — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (113.27) (108.21) (81.27) (81.25) — — —
EBT
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (174.14%) (147.27%) (96.04%) (116.66%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (113.31) (108.30) (81.28) (81.27) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.49 9.30 8.27 6.06 — — —
Depreciation
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.42 1.53 1.43 0.78 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (2.48) (2.25) (1.37) (0.91) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.54) (1.17) (0.76) (0.84) — — —
Cash Flow/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.09) (0.23) (0.02) (0.05) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.63) (1.39) (0.78) (0.89) — — —
Free CF/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.77 2.69 3.43 2.93 ‡‡‡‡ — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 45.71 48.18 59.25 89.24 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.41 1.34 4.05 10.20 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.42 0.76 1.69 2.72 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.41) 0.43 2.42 7.43 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.22 (0.47) (4.40) (6.52) — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (70.23) (56.26) (45.15) (74.95) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (49.90) (10.91) (1.36) (4.50) — — —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (120.13) (67.17) (46.51) (79.45) — — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 166.57 99.51 171.89 228.32 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.03 — — — — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (118.63) (114.18) (185.01) (239.95) — — —
Net Debt
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 218.14 129.44 202.96 261.19 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.88%) (41.83%) (32.82%) (26.89%) — — —
ROA
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.56%) (450.20%) (237.72%) (259.21%) — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.89%) (62.31%) (48.91%) (35.02%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Personalis, Inc. (PSNL) stands at the forefront of precision oncology, leveraging its tumor-informed liquid biopsy platform like NeXT Personal to disrupt cancer diagnostics in a $10B+ market growing at 15-20% annually. Despite biotech volatility—including post-IPO hype, pandemic setbacks, and 2022’s 24% revenue dip to $65M amid layoffs—the company rebounded strongly, hitting $84.6M in 2024 with revenue per employee surging 13% to $369K, signaling lean efficiency. Analysts forecast a brief 2025 dip to $69M before accelerating to $108M by 2027, driven by FDA breakthrough designations and expanding test menus.

Financials show a clear path to profitability: gross margins jumped 28% to 31.7% in 2024, losses shrank 28% to $81M, and EPS improved 45% to -$1.37, bolstered by an 88% capex cut and a net cash position of $185M for multi-year runway. Trading at undervalued multiples (EV/Sales 2.42x vs. projected 6.56x by 2027), the stock offers 22-58% upside to analyst targets, decoupling from past lows amid ROIC gains.

Catalysts like Merck partnerships, AI-enhanced sequencing, and immunotherapy monitoring fuel explosive potential, outweighing risks from competition and reimbursement. With insider sells routine but no exodus, PSNL presents classic biotech asymmetry—depressed prices masking revolutionary upside in precision medicine.

Read full commentary →

Personalis, Inc. (PSNL) Latest News

News by impact score

Fine-tune

27 Aug

5 , 6:01 PM
Tempus AI shares rose after Moderna's melanoma trial success, potentially validating its $1.5 billion Personalis acquisition. Personalis faces transformative shift from $1.5 billion Tempus acquisition now potentially validated by Moderna's melanoma results.

26 Aug

3 www.barchart.com, 11:50 AM
Personalis stock has gained 250% over the past year. The company must now deliver profitability to sustain its trajectory. Profitability requirement represents a key operational milestone that could shape investor views but remains one factor among others.

22 Aug

4 , 4:08 AM
Tempus AI shares surge 39.5% after positive mRNA melanoma trial results and a partnership deal with Personalis. Partnership with Tempus AI after melanoma trial success strengthens Personalis competitive position and growth outlook.

20 Aug

3 stocktwits.com, 1:22 PM
TEM stock heads for best week in 4 months after spotlight on its deal with Personalis, Inc. (PSNL). Deal spotlight with TEM lifts Personalis visibility and near-term market sentiment without altering core trajectory.

4 Aug

3 , 4:01 PM
Personalis, Inc. reported second quarter financial results along with recent business highlights. Quarterly results deliver financial metrics that can shift near-term investor views but rarely redefine long-term trajectory alone.

1 Aug

4 , 10:10 AM
Tempus AI returned to Q2 profit, raised its outlook, and struck a deal with Personalis that could shape investor reactions to both stocks. Personalis lands a direct commercial partnership with Tempus AI after the latter's profit recovery and raised guidance.

31 Jul

3 transcript www.marketbeat.com, 10:03 PM
Tempus AI Q2 results highlight revenue growth in oncology testing and AI platform adoption, signaling stronger competitive pressure in precision medicine and genomics diagnostics markets where Personalis operates. Competitor earnings details indicate moderate shifts in market dynamics and investor focus that could influence Personalis near-term sentiment without immediate fundamental changes.

30 Jul

3 www.barchart.com, 9:15 AM
Tempus AI investors should note July 30 for Personalis, Inc. (PSNL) developments that may affect competitive positioning in precision oncology and genomic testing markets. July 30 developments at Personalis may moderately shift competitive dynamics and investor views in the shared oncology diagnostics space.

22 Jul

4 www.thestreet.com, 8:37 PM
Tempus commits $1.5 billion to dominate the cancer-test market, intensifying competition against companies like Personalis in oncology diagnostics. Tempus's $1.5B market push directly threatens Personalis's competitive standing in cancer testing.

21 Jul

5 qz.com, 8:30 AM
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion. Acquisition by Tempus AI for $1.5 billion ends Personalis independence and redefines its market trajectory.

5 www.medicaldevice-network.com, 7:43 AM
Tempus AI acquires Personalis in a $1.5bn precision oncology deal. Acquisition by Tempus AI for $1.5 billion ends Personalis's independent operations and redefines its market trajectory.

5 , 5:10 AM
Tempus AI acquires Personalis for $1.5 billion to strengthen cancer monitoring operations. The $1.5 billion acquisition by Tempus AI fundamentally alters Personalis's market position and long-term trajectory.

4 , 8:19 PM
Tempus AI comments on its deal with Personalis and assesses whether the bullish outlook for Personalis is already reflected in current valuations. The Tempus AI partnership represents a major strategic collaboration that can materially expand Personalis revenue streams and competitive positioning.

20 Jul

5 , 4:56 PM
Tempus AI acquires Personalis in a $1.7 billion precision oncology deal. The $1.7 billion acquisition by Tempus AI ends Personalis's independent operations and redefines its market trajectory.

5 , 3:19 PM
Tempus AI acquires cancer test maker Personalis in a deal with premium well above peers per Needham. Acquisition by Tempus AI redefines Personalis ownership and long-term trajectory.

5 www.marketbeat.com, 12:02 PM
Tempus AI acquires Personalis to expand MRD testing capabilities and market reach. Acquisition by Tempus AI fundamentally redefines Personalis operations and competitive position.

5 , 11:30 AM
Tempus AI acquires Personalis for $1.5 billion, triggering a decline in PSNL shares. The $1.5 billion acquisition by Tempus AI ends Personalis independence and resets its market trajectory.

5 www.proactiveinvestors.com, 11:23 AM
Tempus AI acquires Personalis for $1.5B. Acquisition by Tempus AI for $1.5B fundamentally redefines Personalis operations and long-term prospects.

5 , 10:44 AM
Tempus AI acquires Personalis for $1.5 billion, triggering immediate stock price declines for both companies. Acquisition eliminates Personalis as an independent public company and shifts its entire future trajectory under Tempus AI ownership.

5 www.medtechdive.com, 10:38 AM
Tempus acquires cancer test-maker Personalis for $1.5 billion. Acquisition by Tempus for $1.5B fundamentally changes Personalis ownership and operations.

5 , 8:56 AM
Tempus AI acquires Personalis in $1.5 billion deal. Acquisition by Tempus AI for $1.5 billion ends Personalis independent operations and market trajectory.

5 , 8:35 AM
Tempus acquires Personalis to integrate its molecular residual disease capabilities more tightly into an AI-enabled precision oncology platform. Acquisition by Tempus fundamentally redefines Personalis competitive position and long-term prospects via MRD integration.

5 , 8:30 AM
Tempus acquires Personalis to integrate molecular residual disease capabilities into its AI-enabled precision oncology platform. Full acquisition by Tempus ends Personalis' independent operations and redefines its trajectory.

4 stocktwits.com, 3:38 PM
Personalis (PSNL) and Tempus AI (TEM) stocks decline after their deal announcement, but Morgan Stanley remains positive on the transaction's strategic value for Personalis. The Tempus AI deal constitutes a major strategic alliance that can significantly shift Personalis's competitive trajectory and growth prospects.

4 stocktwits.com, 11:11 AM
TEM acquires PSNL, unlocking $20B cancer market opportunity as retail investors await execution. TEM acquisition directly enables PSNL entry into $20B cancer market with major strategic implications.

17 Jul

4 , 9:41 AM
Merck reportedly enters takeover battle for Personalis, driving sharp gains in PSNL shares. Merck participation in takeover battle signals potential acquisition that would reshape Personalis ownership and strategy.

14 Jul

4 , 6:00 AM
Personalis receives UKCA marking for NeXT Personal, enabling MRD testing access and biopharma support expansion in Great Britain to accelerate global growth. UKCA marking opens NeXT Personal MRD testing and biopharma services in Great Britain, materially widening addressable markets and revenue channels.

9 Jun

3 Business Wire, 6:00 AM
Personalis launches CE-IVD marked specimen collection kits to enable expanded support for global biopharma clients. CE-IVD marking expands international regulatory compliance and biopharma reach for Personalis operations.

2 Jun

3 Business Wire, 6:00 AM
Personalis presented data at ASCO 2026 on early colorectal cancer recurrence detection and ultrasensitive MRD performance across multiple tumor types. Conference data on MRD detection can moderately lift investor views on Personalis technology.

26 May

3 Business Wire, 6:00 AM
Personalis to present NeXT Personal ultra-sensitive ctDNA data at ASCO 2026 including TRACERx Consortium podium presentation. Conference data highlight can lift visibility and sentiment around ctDNA platform but does not alter operations or financials.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us